Considering the correlation between integrin β3 and CNS infiltration, which was noticed in our retrospective analysis, strategies targeting integrin β3-FAK-MAPK axis might be an option for the development of alternative therapies to treat T-ALL patients with CNSL. The gene discussed is PTK2; the disease is acute lymphoblastic leukemia.